Literature DB >> 15186727

Cytotoxic difference of T cells expanded with anti-CD3 monoclonal antibody in the presence and absence of anti-CD 28 monoclonal antibody.

Yoshiko Yamada-Ohnishi1, Hiroshi Azuma, Noriko Urushibara, Miki Yamaguchi, Mitsuhiro Fujihara, Tetsuji Kobata, Hisami Ikeda.   

Abstract

Bulk T cells can be expanded by CD3 stimulation alone (CD3-Ts) or by CD3/CD28 dual stimulation (CD3/CD28-Ts) of peripheral blood mononuclear cells (PBMC). However, few reports have described the difference of features between CD3-Ts and CD3/CD28-Ts. PBMC were stimulated with anti-CD3 monoclonal antibody (mAb) alone or co-stimulated with anti-CD3/CD28 mAbs immobilized on plastic plates, in the presence of rhIL-2 for 4 days, subsequently cultured in the presence of rhIL-2 with no antibody then analyzed. The expansion rate was significantly lower for CD3-Ts (965 + 510-fold, n=5) than CD3/CD28-Ts (2263 + 856-fold, n=5) (p<0.05). The CD4/CD8 ratio, the percentage of CD28(+) cell, and the percentage of T cells with no ability to generate intracytoplasmic interleukin-4 (IL-4) or interferon-gamma (IFN-gamma) were all significantly higher, but, phenotypically, memory cells were lower in CD3/CD28-Ts than in CD3-Ts. The levels of activity of both natural killer (NK) and lymphocyte-activated killer (LAK) cells were lower in CD3/CD28-Ts than CD3-Ts. In comparison to CD3-Ts, CD3/CD28-Ts showed impaired migration toward RANTES. In conclusion, T cells expanded with anti-CD3 and anti-CD28 mAbs differ from those expanded with anti-CD3 alone with proliferation, cytotoxicity, chemotaxis, and phenotype. These differences may exert profound influences on the therapeutic potential of output cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15186727     DOI: 10.1089/154732804323099244

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  3 in total

1.  Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma.

Authors:  Hui Liu; Jianyu Li; Fengmei Wang; Yingtang Gao; Ying Luo; Peng Wang; Chenglong Li; Zhengyan Zhu
Journal:  Tumour Biol       Date:  2014-11-24

2.  Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28.

Authors:  Jacalyn Rosenblatt; Zekui Wu; Baldev Vasir; Corrine Zarwan; Richard Stone; Heidi Mills; Thea Friedman; Panagiotis A Konstantinopoulos; Dimitrios Spentzos; Musie Ghebremichael; Kristen Stevenson; Donna Neuberg; James D Levine; Robin Joyce; Dimitrios Tzachanis; Vassiliki Boussiotis; Donald Kufe; David Avigan
Journal:  J Immunother       Date:  2010 Feb-Mar       Impact factor: 4.456

3.  T cell stimulation and expansion by SunTag-based clustering of anti-CD3/CD28 scFv.

Authors:  Kunhong Zhong; Zhiyong Liu; Hongjian Li; Shasha Zhao; Yuelong Wang; Wenhao Guo; Xi Zheng; Hui Yang; Gang Guo; Liangxue Zhou; Jianguo Xu; Aiping Tong
Journal:  Aging (Albany NY)       Date:  2020-06-10       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.